南财智讯9月23日电,昭衍新药(06127.HK)发布须予披露交易公告,于2026年4月20日至2026年9月23日期间,公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品,合计投资金额为人民币5.4亿元。(文章来源:南方财经网)
Source Link南财智讯9月23日电,昭衍新药(06127.HK)发布须予披露交易公告,于2026年4月20日至2026年9月23日期间,公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品,合计投资金额为人民币5.4亿元。(文章来源:南方财经网)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.